1. Cytogenetic Evolution in Myeloid Neoplasms at Relapse after Allogeneic Hematopoietic Cell Transplantation: Association with Previous Chemotherapy and Effect on Survival 
Natalie Ertz-Archambault, Heidi Kosiorek, James L. Slack, Melissa L. Lonzo, Patricia T. Greipp, Nandita Khera, Katalin Kelemen 
Biology of Blood and Marrow Transplantation 
Volume 23, Issue 5, Pages (May 2017)
DOI: /j.bbmt
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Comparison of cytogenetic findings at original diagnosis in patients groups with or without cytogenetic evolution (CGE and non-CGE, respectively). Of 25 patients with CGE at relapse, 7 patients had normal cytogenetic results (28%), 10 had abnormal cytogenetic results with less than 3 abnormalities (40%), and 8 had complex cytogenetic abnormalities (3 or more abnormalities) (32%). Of the 24 patients with no cytogenetic evolution, 15 had a normal karyotype (62%), 5 had abnormal karyotype with less than 3 abnormalities (21%), and 4 had complex karyotype abnormalities (17%).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Comparison of post-transplantation (A) and postrelapse (B) survival in months between the CGE and non-CGE patient groups. Kaplan-Meier survival curves demonstrate a significantly shortened post-transplantation survival in the CGE group (median post-transplantation survival 6.54 months [95% CI, 3.74 to 11.82] in the CGE group versus months [95% CI, 5.72 to 15.44] in the non-CGE group; P = .004). Similarly, a significant difference is observed in the postrelapse survival (median of 1.67 months [95% CI, .73 to 3.58] in CGE group versus median of 7.13 months [95% CI, 2.17 to 8.48] in non-CGE group; P < .001).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions